Palisade Bio (NASDAQ:PALI) Director Acquires 20,000 Shares

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera acquired 20,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was purchased at an average cost of $1.98 per share, with a total value of $39,600.00. Following the acquisition, the director directly owned 356,904 shares of the company’s stock, valued at $706,669.92. This represents a 5.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Robert Jr. Baltera also recently made the following trade(s):

• On Thursday, July 2nd, Robert Jr. Baltera bought 10,000 shares of Palisade Bio stock. The shares were purchased at an average cost of $1.98 per share, for a total transaction of $19,800.00.

Palisade Bio Stock Down 2.9%

PALI stock opened at $2.04 on Tuesday. Palisade Bio, Inc. has a 52-week low of $0.53 and a 52-week high of $2.86. The firm has a market cap of $354.10 million, a P/E ratio of -2.02 and a beta of 1.50. The company’s 50-day simple moving average is $1.91 and its 200-day simple moving average is $1.91.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, analysts anticipate that Palisade Bio, Inc. will post -0.25 earnings per share for the current fiscal year.

Institutional Trading of Palisade Bio

A number of institutional investors have recently made changes to their positions in PALI. Perceptive Advisors LLC purchased a new stake in shares of Palisade Bio during the fourth quarter worth approximately $28,318,000. Commodore Capital LP purchased a new position in Palisade Bio in the 4th quarter valued at $26,896,000. Janus Henderson Group PLC lifted its holdings in Palisade Bio by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock valued at $18,760,000 after purchasing an additional 149,118 shares in the last quarter. Octagon Capital Advisors LP lifted its holdings in Palisade Bio by 7.4% in the 1st quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company’s stock valued at $17,984,000 after purchasing an additional 708,419 shares in the last quarter. Finally, RA Capital Management L.P. acquired a new stake in Palisade Bio during the 4th quarter worth $16,742,000. 11.79% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Wolfe Research initiated coverage on Palisade Bio in a research report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price objective for the company. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Sunday. HC Wainwright reissued a “buy” rating and issued a $2.00 price target on shares of Palisade Bio in a report on Tuesday, June 30th. Weiss Ratings raised shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 29th. Finally, LADENBURG THALM/SH SH upgraded shares of Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $8.83.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.